A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials
- 28 August 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 22 (10), 1963-1966
- https://doi.org/10.1038/leu.2008.225
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.Blood, 2007
- Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemiaBlood, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood, 2006
- Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemiaBlood, 2006
- Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsBlood, 2006
- Serial monitoring of BCR–ABL by peripheral blood real‐time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemiaBritish Journal of Haematology, 2002